EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The health‐economic impact of urine albumin‐to‐creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes

Koichi Asahi, Tsuneo Konta iD, Kouichi Tamura iD, Fumitaka Tanaka iD, Akira Fukui iD, Yusuke Nakamura iD, Junichi Hirose iD, Kenichi Ohara iD, Yoko Shijoh iD, Matthew Carter iD, Kimberley Meredith iD, James Harris iD und 3 weitere

Journal of Diabetes Investigation · 2025-01 · 16 (1) · 108-119

DOI: 10.1111/jdi.14293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 22.11.2024. Verfasst von Koichi Asahi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Iwate, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Creatinine, Renal Insufficiency, Chronic, Cost-Benefit Analysis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health, Labor and Welfare of Japan, Bayer Yakuhin Ltd, Bayer Yakuhin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Introduction This analysis seeks to evaluate the cost‐effectiveness of urine albumin‐to‐creatinine ratio testing compared with urine protein‐creatinine ratio testing and no urine testing for the identification of kidney damage in individuals with type 2 diabetes who have, or are at risk of, chronic kidney disease in Japan. Materials and Methods A health‐economic model estimated the clinical and economic consequences of different tests to evaluate kidney damage in line with Japanese guidelines, taking a Japanese healthcare perspective. Differences in the diagnostic performance of tests were considered by the integration of real‐world Japanese data. Outcomes were considered over a lifetime horizon, and included costs, prevented dialyses, life years gained, quality‐adjusted life years, and incremental cost‐effectiveness ratios.

Results

Repeated urine albumin‐to‐creatinine ratio testing was found to be cost‐effective compared with both urine protein‐creatinine ratio testing and no urine testing, yielding incremental cost‐effectiveness ratios of ¥2,652,693 and ¥2,460,453, respectively.

Conclusions

Repeated urine albumin‐to‐creatinine ratio testing is cost‐effective compared with urine protein‐creatinine ratio testing and no urine testing in Japanese individuals with type 2 diabetes, supporting existing clinical evidence that albumin‐to‐creatinine ratio testing should be used more widely, particularly compared with other urine tests such as urine protein‐creatinine ratio testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2CreatinineRenal Insufficiency, ChronicCost-Benefit AnalysisAlbuminuriaHumansJapanMaleFemaleMiddle AgedAgedBiomarkersQuality-Adjusted Life YearsDiabetic NephropathiesEast Asian People

Stichwörter der Autor:innen

AlbuminuriaCost‐effectiveness analysisDiabetes mellitus

Substanzen

CreatinineBiomarkers

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Iwate, Japan.
  • Department of Public Health and Hygiene, Yamagata University Graduate School of Medicine, Yamagata, Yamagata, Japan.
  • Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
  • Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Minato, Tokyo, Japan.
  • Bayer Yakuhin Ltd, Osaka, Osaka, Japan.
  • Wickenstones Ltd, Carlow, Ireland.

ORCID-Profile: Tsuneo Konta, Kouichi Tamura, Fumitaka Tanaka, Akira Fukui, Yusuke Nakamura, Junichi Hirose, Kenichi Ohara, Yoko Shijoh, Matthew Carter, Kimberley Meredith, James Harris, Örjan Åkerborg, Naoki Kashihara, Takashi Yokoo

Förderung

  • Ministry of Health, Labor and Welfare of Japan
  • Bayer Yakuhin Ltd
  • Bayer Yakuhin

Zitieren

APA

Asahi, K., Konta, T., Tamura, K., Tanaka, F., Fukui, A., Nakamura, Y., Hirose, J., Ohara, K., Shijoh, Y., Carter, M., Meredith, K., Harris, J., Åkerborg, Ö., Kashihara, N., & Yokoo, T. (2025). The health‐economic impact of urine albumin‐to‐creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation, 16(1), 108-119. https://doi.org/10.1111/jdi.14293

Vancouver

Asahi K, Konta T, Tamura K, Tanaka F, Fukui A, Nakamura Y, et al. The health‐economic impact of urine albumin‐to‐creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation. 2025;16(1):108-119. doi:10.1111/jdi.14293

BibTeX
@article{Asahi2025,
  author = {Asahi, Koichi and Konta, Tsuneo and Tamura, Kouichi and Tanaka, Fumitaka and Fukui, Akira and Nakamura, Yusuke and Hirose, Junichi and Ohara, Kenichi and Shijoh, Yoko and Carter, Matthew and Meredith, Kimberley and Harris, James and Åkerborg, Örjan and Kashihara, Naoki and Yokoo, Takashi},
  title = {The health‐economic impact of urine albumin‐to‐creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes},
  journal = {Journal of Diabetes Investigation},
  year = {2025},
  volume = {16},
  number = {1},
  pages = {108--119},
  doi = {10.1111/jdi.14293}
}
Kostenlos starten →